Keyword: AstraZeneca

Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in nondiabetic heart failure patients.

The Chinese approval in January opened up a large market with an estimated 14 million irritable bowel syndrome with constipation patients to Linzess.

AstraZeneca is touting SGLT2 med Farxiga’s cardiovascular outcomes win as a game changer for the market. Turns out the FDA likes those results, too.

Roche’s Tecentriq is the only I-O drug approved in small cell lung cancer. But it may soon have to make some room for AstraZeneca’s Imfinzi.

Now that AstraZeneca has scored its Farxiga outcomes data, it's beefing up its sales team to prepare for an expanded FDA approval.

AstraZeneca's Farxiga has new CV data that could help the entire SGLT2 class—and even pressure heart medicines outside the class, too. 

AstraZeneca and GlaxoSmithKline have locked horns in their battle for respiratory supremacy. Could a trial win and an FDA nod help give AZ a leg up?

AstraZeneca is on its way to scoring a key new nod for SGLT2 diabetes drug Farxiga, and the FDA just sped things up.

Pfizer's mature drugs plunged in China. AZ and GSK race their oral anemia drugs to Asia. Biotech leaders worry IP crackdown will hurt collaboration.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.